Proteomic analyses of readily obtained human fluids (e.g., serum, urine, and saliva) indicate that the diagnosis of complex diseases will be enhanced by the simultaneous measurement of multiple biomarkers from such samples. This paper describes the development of a nanoparticle-based multiplexed platform that has the potential for simultaneous read-out of large numbers of biomolecules. For this purpose, we have chosen pancreatic adenocarcinoma (PA) as a test bed for diagnosis and prognosis. PA is a devastating form of cancer in which an estimated 86% of diagnoses resulted in death in the United States in 2010. The high mortality rate is due, in part, to the asymptomatic development of the disease and the dearth of sensitive diagnostics available for early detection. One promising route lies in the development of a serum biomarker panel that can generate a signature unique to early stage PA. We describe the design and development of a proof-of-concept PA biomarker immunoassay array coupled with surface-enhanced Raman scattering (SERS) as a sensitive readout method.
Proteomic analyses of readily obtained human fluids (e.g., serum, urine, and saliva) indicate that the diagnosis of complex diseases will be enhanced by the simultaneous measurement of multiple biomarkers from such samples. This paper describes the development of a nanohemical">particle-based multiplexed platform that has the potential for simultaneous read-out of large numbers of biomolecules. For this purpose, we have chosen pan class="Disease">pancreatic adenocarcinoma (PA) as a test bed for diagnosis and prognosis. PA is a devastating form of cancer in which an estimated 86% of diagnoses resulted in death in the United States in 2010. The high mortality rate is due, in part, to the asymptomatic development of the disease and the dearth of sensitive diagnostics available for early detection. One promising route lies in the development of a serum biomarker panel that can generate a signature unique to early stage PA. We describe the design and development of a proof-of-concept PA biomarker immunoassay array coupled with surface-enhanced Raman scattering (SERS) as a sensitive readout method.
Authors: H Yamamoto; F Itoh; S Iku; Y Adachi; H Fukushima; S Sasaki; M Mukaiya; K Hirata; K Imai Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: Diane M Simeone; Baoan Ji; Mousumi Banerjee; Thiruvengadam Arumugam; Dawei Li; Michelle A Anderson; Ann Marie Bamberger; Joel Greenson; Randal E Brand; Vijaya Ramachandran; Craig D Logsdon Journal: Pancreas Date: 2007-05 Impact factor: 3.327
Authors: M Pla-Roca; R F Leulmi; S Tourekhanova; S Bergeron; V Laforte; E Moreau; S J C Gosline; N Bertos; M Hallett; M Park; D Juncker Journal: Mol Cell Proteomics Date: 2011-12-14 Impact factor: 5.911
Authors: Stephanie T Chang; Jacob M Zahn; Joe Horecka; Pamela L Kunz; James M Ford; George A Fisher; Quynh T Le; Daniel T Chang; Hanlee Ji; Albert C Koong Journal: J Transl Med Date: 2009-12-11 Impact factor: 5.531
Authors: I A Brezestean; N Tosa; A Falamas; D Cuibus; C M Muntean; A Bende; B Cozar; C Berghian-Grosan; C Farcău Journal: Front Chem Date: 2022-06-29 Impact factor: 5.545
Authors: Georgina Gonzalez-Avila; Bettina Sommer; A Armando García-Hernandez; Carlos Ramos; Edgar Flores-Soto Journal: Front Mol Biosci Date: 2022-06-01